Liquid Biopsy Predicts Early Lung Cancer Relapse

Whole-genome sequencing of circulating tumor DNA could identify patients at risk of recurrence more than a year before conventional imaging

November 2, 2026
3 min

The Pathologist

At a Glance

Category	Detail
Condition	Postoperative recurrence of stage IA lung adenocarcinoma
Key Mechanisms	Whole-genome sequencing of tumor and matched normal tissue establishes a patient-specific genetic fingerprint; an AI-supported algorithm searches follow-up blood samples for matching circulating tumor DNA.
Target Population	Patients with stage IA lung adenocarcinoma after surgery; the study included 42 patients.
Care Setting	Postoperative surveillance and follow-up for stage IA lung adenocarcinoma, where current monitoring relies primarily on imaging.

Key Highlights

The retrospective study analyzed 331 blood samples from 42 patients with stage IA lung adenocarcinoma.
The WGS-based approach predicted recurrence with 75% sensitivity and 83% specificity.
Nine of 12 patients who experienced recurrence had detectable ctDNA.
In six patients, a positive ctDNA test preceded clinical or imaging confirmation by a median of 16.7 months.
The study requires prospective validation; integration with imaging and effects on patient outcomes remain to be established.

Guideline-Based Recommendations

Diagnosis

The study used WGS of each patient's original tumor and matched normal tissue to establish an individual genetic fingerprint, then searched follow-up blood samples for matching ctDNA.

Management

The article reports that ctDNA analysis could help identify patients who may benefit from additional treatment, but does not establish a treatment recommendation.
Further studies are needed to determine how molecular monitoring should be integrated with imaging.

Monitoring & Follow-up

Current postoperative follow-up relies primarily on imaging.
The study evaluated ctDNA testing in blood samples collected during treatment and follow-up.

Risks

The evidence comes from a small retrospective study and requires prospective validation.
The article identifies sample collection, testing costs, and use of routinely processed pathology specimens as challenges.
Whether earlier molecular detection improves patient outcomes has not been established.

Patient & Prescribing Data

The retrospective study included 42 patients with stage IA lung adenocarcinoma; 12 experienced recurrence.

The article describes a potential role for ctDNA testing in identifying residual disease and informing surveillance or intervention, but provides no established prescribing regimen or treatment-effect data.

Clinical Best Practices

Interpret the reported performance in the context of the study's small, retrospective cohort.
Do not treat the reported lead time as evidence that earlier detection improves outcomes; the article states that this requires further study.
Consider that WGS distinguished recurrent disease from a second primary lung tumor in the study, a distinction that can be difficult using conventional pathology alone.